Company intelligence / Profile preview
Pheno Therapeutics
Edinburgh, Scotland, United Kingdomphenotherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Pheno Therapeutics has advanced its lead small molecule GPR17 antagonist candidate PTD802 into first-in-human clinical trials targeting remyelination in multiple sclerosis. The company leverages a proprietary phenotypic screening platform to identify novel neuroprotective agents focused on oligodendrocyte biology. No published clinical results yet; the company recently received regulatory approval to begin human studies.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (GPR17 antagonists)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
UCB (exclusive worldwide license agreement for PTD802 program)
Beyond the preview
Go deeper on Pheno Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pheno Therapeutics.